background
atop
sensit
hous
dust
mite
hdm
associ
alter
antibodi
respons
nasopharyng
colon
bacterium
haemophilu
influenza
children
admit
emerg
depart
asthma
exacerb
reduc
igg
respons
hdm
allergen
object
investig
antibacteri
antiallergen
antibodi
respons
convalesc
asthma
exacerb
differ
found
exacerb
associ
without
viral
infect
result
ige
antibodi
bacteri
antigen
increas
sera
convalesc
mani
children
achiev
titr
high
ige
titr
allergen
contrast
ige
antihdm
titr
declin
convalesc
antibacteri
ige
titr
subject
without
viru
infect
antihdm
ige
declin
rapidli
virusinfect
subject
igg
titr
major
hdm
allergen
show
consist
increas
overal
igg
antihdm
titr
even
declin
subject
without
viru
infect
antibacteri
igg
antibodi
contrast
ige
chang
patient
frequent
episod
persist
asthma
similar
ige
antibacteri
titr
patient
infrequ
asthma
acut
phase
although
reduc
igg
titr
bacteria
hdm
conclus
period
follow
acut
exacerb
asthma
mark
specif
increas
antibacteri
ige
compar
reduc
ige
respons
hdm
provid
support
concept
thelper
type
respons
bacteri
antigen
play
role
asthma
pathogenesi
exacerb
asthma
hous
dust
mite
hdm
allerg
peopl
usual
result
nonallergen
trigger
viru
infect
act
inflam
airway
rather
increas
respons
allergen
recent
studi
ige
antihdm
antibodi
profil
children
attend
emerg
depart
howev
show
hdmallerg
children
exacerb
similar
ige
respons
allerg
children
commun
cohort
strikingli
reduc
antibodi
preval
reduc
suggest
igg
antibodi
could
direct
protect
effect
shown
experiment
model
marker
regulatori
respons
allerg
sensit
also
associ
aberr
antibodi
respons
antigen
author
shown
decreas
antibodi
protect
outer
membran
protein
antigen
nasopharyng
colon
bacterium
haemophilu
influenza
infanc
product
antibodi
atop
nonatop
peopl
asthma
exacerb
associ
intensifi
inflamm
increas
clinic
mechan
allerg
diseas
current
address
central
clinic
school
univers
sydney
thelper
type
cytokin
product
decreas
ifng
may
influenc
antibodi
respons
studi
accordingli
examin
antiallergen
antibodi
respons
exacerb
convalesc
possibl
bystand
effect
judg
antibodi
respons
outer
membran
protein
rhinoviru
rv
infect
detect
mani
children
respons
absenc
presenc
known
viru
infect
examin
convalesc
associ
decreas
ige
antiallergen
antibodi
increas
igg
also
chang
igg
antibodi
antigen
even
though
hdm
found
decreas
subject
frequent
episod
persist
asthma
strikingli
convalesc
children
increas
ige
outer
membran
protein
titr
often
similar
induc
major
allergen
pair
acut
convalesc
plasma
examin
hdmallerg
children
present
emerg
depart
princess
margaret
hospit
children
pmh
acut
asthma
tabl
peripher
blood
sampl
obtain
soon
possibl
initi
treatment
within
h
present
hospit
plasma
store
blood
sampl
obtain
acut
attack
child
clinic
well
median
time
acut
convalesc
visit
week
interquartil
rang
week
standard
manag
children
present
asthma
exacerb
pmh
includ
oxygen
supplement
satur
b
agonist
salbutamol
anticholinerg
ipratropium
bromid
via
meter
dose
inhal
larg
volum
spacer
interv
first
hour
prednisolon
mgkg
maximum
mg
oral
oral
steroid
rare
use
beyond
day
exacerb
antibiot
administ
admiss
one
child
histori
record
antibiot
use
either
acut
attack
convalesc
sever
acut
asthma
attack
present
determin
use
previous
valid
score
system
possibl
score
determin
subject
mild
moder
sever
pattern
asthma
sever
also
assess
accord
nation
asthma
council
australia
guidelin
determin
whether
children
suffer
infrequ
episod
frequent
episod
persist
asthma
exacerb
parent
particip
gave
inform
consent
ethic
committe
king
edward
memori
princess
margaret
hospit
western
australia
approv
studi
acut
present
pernas
aspir
pna
collect
use
suction
cathet
attach
lowpressur
suction
unit
secret
aspir
mucou
trap
secret
elut
ml
salin
transport
immedi
laboratori
detect
common
viral
respiratori
pathogen
pna
collect
hdmallerg
children
admiss
hospit
order
identifi
presenc
viral
infect
respiratori
syncyti
viru
rsv
adenoviru
ad
influenza
infv
parainfluenza
piv
virus
either
identifi
direct
immunofluoresc
use
virusspecif
monoclon
antibodi
isol
cell
cultur
llcmk
mrc
cell
line
identifi
indirect
pmh
subiaco
western
australia
rv
human
metapneumoviru
mpv
coronaviru
cov
detect
rna
extract
rtpcr
rv
cov
identifi
pathwest
qeii
medic
centr
nedland
western
australia
mpv
identifi
pmh
sampl
reanalys
respiratori
multicodeplx
assay
rma
new
multiplex
pcr
assay
confirm
detect
presenc
rsv
ad
infv
piv
rv
mpv
cov
enteroviru
rma
assay
detect
copi
cdna
detect
posit
rv
sampl
pcr
assay
conduct
pathwest
time
lower
detect
rate
pcr
due
defici
assay
subsequ
amend
sampl
test
recent
gave
result
rma
outer
membran
protein
h
influenza
eagen
isol
produc
fusion
polypeptid
glutathionestransferas
gst
gst
control
produc
directli
also
made
ntermin
hexahistidin
tag
confirm
bind
due
compon
gst
tag
natur
der
p
purifi
spent
mite
medium
antibodi
affin
chromatographi
natur
der
p
purifi
accord
heymann
et
al
substrat
purifi
benzamidin
sepharos
amersham
pharmacia
biotech
ab
uppsala
sweden
natur
der
p
purifi
substrat
affin
bcyclodextrin
sepharos
amersham
pharmacia
biotech
ab
recombin
der
p
der
p
der
p
produc
recombin
polypeptid
ntermin
hexahistidin
tag
purifi
ninta
qiagen
hilden
germani
protein
purifi
highresolut
size
exclus
chromatographi
pass
mustang
e
filter
pall
life
scienc
new
york
ny
usa
remov
residu
endotoxin
prepar
delfia
tm
wallac
turku
finland
assay
use
quantifi
ige
bind
antigen
panel
mite
allergen
der
p
quantiti
antibodi
interpol
standard
curv
creat
humanmous
antid
p
chimer
antibodi
indoor
biotechnolog
ltd
cardiff
uk
procedur
schuurman
et
al
ige
igg
delfia
tm
assay
describ
detail
elsewher
lower
limit
detect
ige
antibodi
bind
ngml
respect
consist
expect
perform
delfia
tm
standard
curv
dynam
rang
neg
valu
given
lower
limit
detect
antibodi
assay
result
given
either
titr
individu
allergen
summat
respons
person
allergen
sum
specif
so
antibodi
data
highli
skew
logtransform
analysi
total
plasma
ige
level
normal
transform
mean
confid
interv
ci
calcul
differ
total
plasma
level
group
normal
data
compar
pair
unpair
ttest
differ
level
specif
antibodi
bind
select
group
compar
either
nonparametr
mannwhitney
wilcoxon
sign
rank
test
w
test
analys
done
use
spss
window
chicago
il
usa
pair
acut
convalesc
plasma
hdmallerg
children
avail
measur
ige
igg
antibodi
titr
specif
hdm
allergen
shown
scatter
distribut
fig
ige
titr
lower
allergen
convalesc
plasma
statist
signific
der
p
der
p
der
p
der
p
antibodi
der
p
der
p
make
half
antihdm
ige
respons
track
individu
decreas
major
subject
fig
averag
titr
reduc
two
threefold
still
high
level
igg
antibodi
respons
direct
major
der
p
der
p
allergen
report
previous
preval
titr
preval
show
consist
chang
convalesc
period
titr
patient
remain
undetect
fig
concord
patient
variat
antid
p
der
p
titr
outlin
introduct
young
children
develop
atopi
reduc
antibodi
bacteri
antigen
atop
peopl
age
much
greater
propens
make
highli
associ
subclass
antibodi
ige
antibodi
accordingli
measur
examin
titr
present
chang
convalesc
period
antibodi
readili
detect
chang
convalesc
period
fig
detect
less
frequent
show
consist
chang
convalesc
contrast
ige
antibodi
show
increas
hdmallerg
plasma
convalesc
children
meant
develop
previous
undetect
respons
individu
respons
reach
titr
ngml
children
admit
emerg
depart
wide
rang
previou
experi
asthma
might
expect
greater
histori
diseas
would
differ
antibodi
titr
antibodi
respons
plasma
children
infrequ
episod
asthma
exacerb
compar
respons
children
either
frequent
episod
persist
asthma
exacerb
signific
differ
comparison
viru
posit
neg
group
either
acut
convalesc
measur
hdm
hous
dust
mite
so
sum
specif
convalesc
titr
ige
immunoglobulin
ige
antibodi
hdm
allergen
decreas
major
children
occur
major
der
p
der
p
well
midpot
der
p
allergen
differ
acut
convalesc
ige
antihdm
titr
viru
posit
viru
neg
group
analys
separ
patient
without
viru
infect
show
twofold
reduct
titr
averag
titr
viru
posit
group
reduc
sixfold
statist
signific
possibl
reason
rv
infect
caus
transient
increas
present
greater
declin
convalesc
reduct
howev
view
context
ige
titr
detect
exacerb
higher
detect
children
stabl
asthma
decreas
usual
level
still
within
rang
commonli
found
exacerb
children
administ
increas
medic
exacerb
particularli
corticosteroid
treatment
report
investig
could
possibl
caus
declin
howev
regardless
mechan
respons
decreas
ige
reduct
would
benefici
patient
well
reduc
respons
hdm
allergen
decreas
total
ige
would
reduc
allergenindepend
bind
activ
mast
cell
stabil
receptor
express
previous
found
children
recruit
emerg
depart
asthma
exacerb
markedli
less
igg
antibodi
mite
allergen
children
stabl
asthma
preval
compar
individu
chang
igg
found
convalesc
titr
remain
neg
igg
respons
thu
restor
period
convalesc
remain
import
featur
studi
suscept
acut
attack
asthma
summat
titr
hdm
allergen
analys
fact
declin
convalesc
period
group
without
associ
rv
infect
potenti
signific
low
igg
antibodi
underscor
find
summat
titr
hdm
allergen
lowest
patient
frequent
episod
persist
asthma
anim
studi
demonstr
sever
mechan
igg
antibodi
amelior
allerg
respons
vivo
sustain
low
titr
children
exacerb
associ
low
titr
persist
diseas
suggest
may
protect
human
asthma
previou
studi
measur
antibodi
outer
membran
protein
h
influenza
potenti
mucos
bystand
antigen
respons
allergen
dysregul
respons
found
atop
infant
show
slow
develop
antibodi
atop
subsequ
develop
antibodi
isotyp
rare
found
antibodi
respons
nonatop
subject
although
regul
igg
subclass
human
show
clear
demarc
cytokin
regul
found
mice
still
investig
antibodi
strongli
associ
respons
preferenti
upregul
transcript
factor
observ
show
igg
respons
chang
studi
period
follow
exacerb
particular
induc
support
idea
bystand
regul
strike
unexpect
find
howev
made
show
children
develop
ige
antibodi
convalesc
either
increas
preexist
titr
appear
undetect
level
therefor
evid
possibl
cytokin
produc
exacerb
direct
antibacteri
respons
antibodi
isotyp
presenc
ige
antibodi
bacteria
includ
h
influenza
known
time
quantit
assay
use
reveal
high
frequenc
also
antibodi
level
consider
magnitud
number
children
develop
titr
ng
igeml
rais
possibl
ige
interact
bacteri
antigen
may
even
effect
prolong
inflamm
comparison
median
antifel
ige
titr
peopl
rhinoconjunct
cat
ngml
titr
even
reach
level
respons
major
hdm
allergen
hdmsensit
children
studi
measur
trombon
et
al
bacteria
usual
present
concentr
ml
aspir
reason
scope
antigenantibodi
interact
similar
respons
colon
bacteria
must
also
consid
unlik
ige
direct
role
exacerb
titr
low
time
matter
specul
whether
upregul
requir
increas
exposur
antigen
recrudesc
exist
infect
new
colon
increas
ige
antibodi
face
decreas
antihdm
ige
titr
might
suggest
declin
antihdm
ige
antibodi
due
glucocorticoid
administr
inde
data
show
glucocorticoid
vari
effect
ige
product
effect
corticosteroid
depend
differenti
state
target
cell
control
limit
respons
steroid
exampl
inhibit
earli
bcell
respons
increas
later
immunoglobulin
switch
result
reminisc
report
diazsanchez
et
al
show
steroid
markedli
inhibit
mucos
ige
antibodi
respons
patient
challeng
ragwe
allergen
time
margin
effect
adjuv
activ
extract
measur
increas
total
ige
immunoglobulin
present
data
similar
antiallergen
respons
inhibit
much
greater
degre
ige
immunoglobulin
titr
antibodi
bystand
antigen
increas
studi
protect
antigen
bacterium
highli
conserv
sequenc
present
isol
induc
antibodi
respons
children
success
colon
predomin
nontyp
organ
shown
recent
studi
expect
occur
sever
time
year
studi
environ
univers
hib
vaccin
sinc
almost
complet
erad
type
b
diseas
excel
complianc
programm
hib
infect
vaccin
would
influenc
result
shown
moreov
although
studi
australia
hib
vaccin
shown
almost
elimin
abil
detect
type
b
carriag
england
countri
similar
socioeconom
environ
well
possibl
antibacteri
ige
could
involv
inflamm
ige
may
marker
induct
dysregul
immun
could
contribut
co
morbid
asthma
bacteri
infect
recent
studi
bisgaard
also
shown
bacteri
colon
especi
h
influenza
strong
risk
factor
recurr
wheez
asthma
earli
life
possibl
immun
respons
colon
bacteria
may
import
relationship
allerg
diseas
consider
pathophysiolog
signific
ige
antibodi
includ
possibl
similar
parallel
respons
h
influenza
epitop
antigen
colon
bacteria
occur
gramneg
bacteria
includ
h
influenza
activ
mechan
constitut
releas
outer
membran
vesicl
mm
would
contain
antigen
could
distribut
airway
local
igemedi
inflammatori
respons
also
system
effect
exampl
demonstr
thymic
stromal
lymphopoietin
tslp
cytokin
induc
fceridepend
respons
mast
cell
suggest
studi
astrakhan
tslp
deriv
local
site
might
impair
tolerogen
bcell
respons
promot
allerg
respons
new
specif
antibacteri
ige
produc
convalesc
seem
stem
exacerb
produc
children
regardless
clinic
histori
evid
viral
infect
low
titr
found
subject
frequent
persist
asthma
low
present
convalesc
investig
role
suscept
asthma
marker
defin
suscept
children
becom
appar
viru
especi
rv
infect
may
preval
caus
exacerb
asthma
infect
could
drive
cytokin
respons
bia
detail
virolog
perform
subject
found
detect
infect
rv
symptom
present
averag
wors
infect
subject
none
ige
antibodi
immunoglobulin
measur
present
high
group
differ
induct
ige
antibodi
also
similar
infect
uninfect
group
possibl
differ
howev
indic
larger
declin
antihdm
ige
infect
group
decreas
alreadi
low
igg
antihdm
antibodi
titr
uninfect
infect
group
summari
children
convalesc
asthma
exacerb
without
detect
viru
infect
develop
increas
ige
antibodi
antigen
bacterium
h
influenza
decreas
ige
antibodi
hdm
allergen
low
igg
antihdm
antibodi
previous
report
children
admit
emerg
depart
exacerb
increas
even
decreas
children
associ
viral
infect
ige
titr
develop
could
high
titr
frequent
found
allergen
may
play
role
maintain
allerg
sensit
indic
deviat
protect
immun
